Intelligence Unit Special Reports Special Events Subscribe Sponsored Departments Follow Us

Twitter Facebook LinkedIn RSS

FDA Adds Contrast Agent Label Warning



The U.S. Food and Drug Administration has set label requirements for gadolinium-based contrast agents used in MR imaging to minimize causing the rare but serious kidney dysfunction condition called nephrogenic systemic fibrosis.


Name:
E-mail:
Website:  
Please enter your comment below:
Please enter the text below: